Double High Risk Atrial Fibrillation PatientÃâÃÂ´s

Antonio L Aguilar-Shea

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Double High Risk Atrial Fibrillation Patient�?´s

Antonio L Aguilar-Shea^*
Centro de Salud Puerta de Madrid, Spain
*Corresponding Author :	Antonio L Aguilar-Shea Centro de Salud Puerta de Madrid Avda. del Ejército 61 28802 Alcalá de Henares (Madrid), Spain Tel: +34918806699 Fax: +34918823392 E-mail: antonio.aguilar@salud.madrid.org
Received date: April 14, 2016; Accepted date: April 15, 2016; Published date: April 19, 2016
Citation: Aguilar-Shea AL (2016) Double High Risk Atrial Fibrillation Patient´s. Arrhythm Open Access 1:e103. doi:10.4172/atoa.1000e103
Copyright: © Aguilar-Shea AL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at

View PDF Download PDF

Editorial

Atrial fibrillation is the most frequent arrhythmia which must be managed properly. As part of the evaluation and treatment, preventing embolism is a key in these patients. The two groups of drugs used to prevent embolism are oral anticoagulants and antiplatelets. The major secondary effect of both of these agents is bleeding, so a balance between preventing embolism and avoiding bleeding must be achieved. To make the correct decision scale CHA2DS2-VASc will help in the aid of embolism prevention and HASBLED scale will help in the bleeding evaluation. CHA2DS2-VASc punctuation equal or over 2 indicates necessity for oral anticoagulation and HASBLED equal or over 3 indicates a high risk of bleeding. The situation of high risk of embolism and high risk of bleeding is not infrequent and requires a correct management.

To give response to the question of what to do with patients with atrial fibrillation with a high risk of embolism and a high risk of bleeding, the main guidelines were reviewed: European Society of Cardiology [1], Uptodate [2], American College of Cardiology/ American Heart Association [3], National Institute for Health and Care Excellence (NICE) [4] and Cochrane Database [5,6]. The conclusions are that the new oral anticoagulants (apixaban, rivaroxaban and dabigatran) are the treatment of choice in these cases because the risk of bleeding of the new oral anticoagulants is lower when compared to warfarin and high risk of bleeding is not a reason for anticoagulant therapy exclusion.

References